Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.
We show that the dual 5-α reductase enzyme inhibitor dutasteride prevents enhanced growth of both benign and malignant prostate cell lines, incubated with physiologic to supraphysiologic doses of testosterone. Using androgen-sensitive benign BPH-1 cells, LNCaP cancer cells, their derivative C4-2 cells, or Dunning rat cancer cells, we subjected 30,000 cells/well to concomitant treatment with 10(-9), 10(-8), or 10(-7) M testosterone in the presence of low (0.25 μM) or high (1.0 μM) doses of dutasteride. Both low- and high-dose dutasteride abrogated testosterone-stimulated growth of all 4 cell lines. If the in vitro data mimic conditions in men undergoing testosterone replacement, concomitant dutasteride use might make testosterone safe for men with benign prostatic hypertrophy, latent prostate cancer and perhaps even aggressive prostate cancer. Testosterone might also be used to prevent the rare anti-androgen side effects of dutasteride when used for benign prostatic hypertrophy and baldness. Further clinical investigation is indicated.
Alisky
Joseph M
JM
Tang
Yaqiong
Y
Habermehl
Gabriel K
GK
Iczkowski
Kenneth A
KA
J Clin Endocrinol Metab. 2004 Aug;89(8):3821-9
15292312
J Urol. 2008 May;179(5):1736-40
18343414
Eur Urol. 2005 Nov;48(5):739-44
16203079
Prostate. 2006 Sep 1;66(12):1319-28
16688747
Prostate. 1999 Jan 1;38(1):46-54
9973109
Cancer Prev Res (Phila). 2009 Jun;2(6):518-24
19491289
Anticancer Res. 2005 May-Jun;25(3B):2075-83
16158948
ScientificWorldJournal. 2009 Jul 27;9:685-90
19649507
Ther Clin Risk Manag. 2009 Jun;5(3):427-48
19707253
Int J Cancer. 1994 May 1;57(3):406-12
8169003